Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells
Advanced Science · 2026
DOI: 10.1002/advs.202521784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Fenglin Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Exosomes, Myeloid-Derived Suppressor Cells, Receptors, IgG, Fibrinogen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Chongqing Medical Leading Talent Project.
Abstract (Originalsprache)
Myeloid‐derived suppressor cells (MDSCs) play a pivotal role in establishing an immunosuppressive tumor microenvironment (TME), yet the mechanisms underlying their functional activation remain incompletely defined. Here, we identify the Fgl2‐FcγRIIB signaling axis as a critical mediator of MDSC‐driven immune evasion across solid tumors. Analysis of clinical specimens revealed that Fgl2 expression is significantly elevated in tumor tissues and inversely correlates with CD8 + T cell infiltration, while positively associating with the accumulation of FcγRIIB + MDSCs and poor patient prognosis. We demonstrate that tumor‐derived exosomes (TEX) function as efficient carriers that deliver membrane‐bound Fgl2 (mFgl2) to MDSCs. These exosomes are internalized by MDSCs through FcγRIIB‐mediated endocytosis, leading to an enhanced immunosuppressive function characterized by upregulated arginase‐1 (Arg‐1) and inducible nitric oxide synthase (iNOS) expression and an increased capacity to suppress CD8 + T cell proliferation. Genetic ablation of FcγRIIB or antibody‐mediated neutralization of Fgl2 abolished this exosome‐mediated immunosuppressive programming, restoring T cell activity and impairing tumor growth in vivo. Importantly, a therapeutic strategy combining an exosome secretion inhibitor, in combination with PD‐L1 blockade and MDSCs depletion, synergistically achieved potent antitumor effects. Our findings unveil a novel exosome‐dependent mechanism through which tumors systemically educate MDSCs, establishing the Fgl2‐FcγRIIB axis as a promising broad‐spectrum target for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, China.
- Department of Hematology and Oncology, 921 Hospital of Joint Logistics Support Force of PLA(the Second Affiliated Hospital of Hunan Normal University), Changsha, China.
- School of Pharmaceutical Engineering, Chongqing Chemical Industry College, Chongqing, China.
ORCID-Profile: Jianguo Sun
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Chongqing Medical Leading Talent Project
Zitieren
APA
Lin, F., Cai, D., Jian, C., Qi, Y., Zheng, L., Yang, Q., Zhang, L., Chen, D., Li, L., Cai, P., Sun, L., Zhang, L., & Sun, J. (2026). Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells. Advanced Science. https://doi.org/10.1002/advs.202521784
Vancouver
Lin F, Cai D, Jian C, Qi Y, Zheng L, Yang Q, et al. Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells. Advanced Science. 2026. doi:10.1002/advs.202521784
BibTeX
@article{Lin2026,
author = {Lin, Fenglin and Cai, Dingqin and Jian, Chunli and Qi, Yaxian and Zheng, Linpeng and Yang, Qiao and Zhang, Longyao and Chen, Diangang and Li, Lingchen and Cai, Ping and Sun, Lingyou and Zhang, Luping and Sun, Jianguo},
title = {Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521784}
}
EUVIMED